Evidence map›Paper›PMID 28973376›Full record

ArticleHuman molecular genetics2017

The integrity and organization of the human AIPL1 functional domains is critical for its role as a HSP90-dependent co-chaperone for rod PDE6.

Almudena Sacristan-Reviriego, James Bellingham, Chrisostomos Prodromou, Annika N Boehm, Annette Aichem, Neruban Kumaran, James Bainbridge, Michel Michaelides, Jacqueline van der Spuy

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Restoring Sight: The Journey of AIPL1 from Discovery to Therapy.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. New focus on regulation of the rod photoreceptor phosphodiesterase.Current opinion in structural biology · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. FKBP Ligands-Where We Are and Where to Go?Frontiers in pharmacology · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Almudena Sacristan-ReviriegoUCL Institute of Ophthalmology, London EC1V 9EL, UK.
James BellinghamUCL Institute of Ophthalmology, London EC1V 9EL, UK.
Chrisostomos ProdromouGenome Damage and Stability Centre, University of Sussex, Brighton, East Sussex BN1 9RQ, UK.
Annika N Boehm
Annette Aichem
Neruban KumaranUCL Institute of Ophthalmology, London EC1V 9EL, UK.
James BainbridgeUCL Institute of Ophthalmology, London EC1V 9EL, UK.
Michel MichaelidesUCL Institute of Ophthalmology, London EC1V 9EL, UK.
Jacqueline van der SpuyUCL Institute of Ophthalmology, London EC1V 9EL, UK.
University College London · GBBiotechnology Institute Thurgau · CHUniversity of Sussex · GB

Funding

Department of Health NIHR-RP-011-003Medical Research Council MR/P02582X/1
6 · The paper itself

Abstract

Biallelic mutations in the photoreceptor-expressed aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) are associated with autosomal recessive Leber congenital amaurosis (LCA), the most severe form of inherited retinopathy in early childhood. AIPL1 functions as a photoreceptor-specific co-chaperone that interacts with the molecular chaperone HSP90 to facilitate the stable assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme. In this study, we characterized the functional deficits of AIPL1 variations, some of which induce aberrant pre-mRNA AIPL1 splicing leading to the production of alternative AIPL1 isoforms. We investigated the ability of the AIPL1 variants to mediate an interaction with HSP90 and modulate the rod cGMP PDE6 stability and activity. Our data revealed that both the FK506 binding protein (FKBP)-like domain and the tetratricopeptide repeat (TPR) domain of AIPL1 are required for interaction with HSP90. We further demonstrate that AIPL1 significantly modulates the catalytic activity of heterologously expressed rod PDE6. Although the N-terminal FKBP-like domain of AIPL1 binds the farnesylated PDE6α subunit through direct interaction with the farnesyl moiety, mutations compromising the integrity of the C-terminal TPR domain of AIPL1 also failed to modulate PDE6 activity efficiently. These AIPL1 variants moreover failed to promote the HSP90-dependent stabilization of the PDE6α subunit in the cytosol. In summary, we have successfully validated the disease-causing status of the AIPL1 variations in vitro. Our findings provide insight into the mechanism underlying the co-chaperone role of AIPL1 and will be critical for ensuring an early and effective diagnosis of AIPL1 LCA patients.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCarrier ProteinsCHO CellsCricetulusCyclic Nucleotide Phosphodiesterases, Type 6Eye ProteinsHEK293 CellsHSP90 Heat-Shock ProteinsHumansLeber Congenital AmaurosisMutationProtein BindingProtein DomainsRetinaRetinal Rod Photoreceptor CellsAdaptor Proteins, Signal TransducingAIPL1 protein, humanCarrier ProteinsCyclic Nucleotide Phosphodiesterases, Type 6Eye ProteinsHSP90 Heat-Shock ProteinsRNA Precursors

Identifiers

PMID28973376
PMCPMC5886190
OpenAlexW2748552713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.